A five year study will investigate
whether aspirin can reduce the
recurrence of bowel cancer, and its
effect on survival after surgery.
The study has had more than
$550,000 in funding approved
through Cancer Australia’s Priority-driven
Collaborative Cancer
Research Scheme and will involve
approximately 1200 patients, with
200 from Australia, co-ordinated
locally by the Australasian Gastro-
Intestinal Trial Group (AGITG).
CA said aspirin was helpful in
preventing and treating heart and
blood vessel diseases and that
there was growing evidence that
aspirin had anticancer properties
as well.
Principal investigator Eva Segelov
said if the study proved aspirin
could prevent bowel cancer
recurring, it would provide a global,
cost effective treatment.The above article was sent to subscribers in Pharmacy Daily's issue from 19 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Dec 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.